- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Ankylosing Spondylitis
Xenofon Baraliakos, MD: Efficacy and Safety of Bimekizumab in Non-Radiographic Axial Spondyloarthritis
November 14, 2022
ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Rheumatology Patients Report High Levels of Satisfaction With Adalimumab Biosimilar
November 13, 2022
ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.
Combination TNFi plus NSAIDs Provided Little Additional Benefit to TNFi Alone for Spinal Progression in r-axSpA
November 12, 2022
Data from the CONSUL trial provide insight into the effects of TNF inhibitor monotherapy compared against combination therapy with NSAIDs for blunting radiographic spinal progression in adults with radiographic axial spondyloarthritis.
Early TNF Inhibitor Initiation in Ankylosing Spondylitis Linked to Increase Cardiovascular Risk
November 12, 2022
An analysis of more than 17,000 Veterans suggests early initiation of TNF inhibitor therapy in patients with ankylosing spondylitis was associated with an increased risk of incident cardiovascular disease and major adverse cardiovascular events.
Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis
June 14, 2022
Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.
Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA
June 03, 2022
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment
June 03, 2022
Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
Poor Exercise Adherence Reported in Patients with Ankylosing Spondylitis
May 11, 2022
Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.
Increased Risk of Aortic Regurgitation, Atrial Fibrillation in Patients With Radiographic Axial Spondyloarthritis
May 04, 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
Secukinumab Improves Disease Activity in Patients With PsA, axSpA
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.